That’s because, in the new frontier of cancer medicine, there is a critical gap between the precision medicine haves and have nots. The vast majority of lung cancer patients being treated outside of major cancer centers don’t benefit from these advances in precision medicine because they are not getting the latest genomic and proteomic tests. Matt Ellefson was living in Sioux Falls, S.D., when he was diagnosed with late-stage lung cancer in 2009. --Sarah Kerruish, Chief Patient Officer, AntidoteNow joined by many leading patient organizations, including PatientsLikeMe, the Lung Cancer Alliance, the Lung Cancer Foundation of America, Free to Breathe, the Bonnie J. Addario Lung Cancer Foundation, H-Labs and the Patient Empowerment Foundation, Precision Medicine For Me was launched in 11 1/2 weeks. In the initial phase, Precision Medicine for Me is focused on lung cancer.

Source: Forbes January 31, 2017 18:10 UTC